{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-000894","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.594475+00:00","generated_at":"2026-06-20T18:21:01.088948+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Provectus outlines 2023 regulatory path for PV-10 in rare in-transit melanoma, updates pipeline","bullets":["Plans regulatory pathway for PV-10 monotherapy to treat rare in-transit melanoma; cites 56% CR in 121 patients.","Plans Phase 2/3 RCT of PV-10 + immune checkpoint blockade vs. monotherapy for Stage III melanoma; prior data shows 50% CR.","2022 achievements: 6 conference presentations, new patents, expanded research collaborations with Moffitt, Rockefeller, Univ. Calgary.","Discovered PV-10 may act as immune adjuvant in vaccines; synthesized second HX molecule; added Dr. Aru Narendran to SAB.","Received WHO INN name 'rose bengal sodium' for pharmaceutical-grade RBS API; option agreement with Univ. Miami for eye infections."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-000894","json":"https://secwatch.observer/filing/0001493152-23-000894.json","markdown":"https://secwatch.observer/filing/0001493152-23-000894.md","text":"https://secwatch.observer/filing/0001493152-23-000894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315223000894/0001493152-23-000894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315223000894/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:21:01.088948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}